{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T19:03:27Z","timestamp":1757617407424,"version":"3.44.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K19522","22H03140","22K08764"],"award-info":[{"award-number":["21K19522","22H03140","22K08764"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>To clarify the status of multigene panel testing for suspected hereditary breast cancer in our institute, and disclose the characteristics of the variants detected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This was a retrospective study of individuals who underwent next-generation sequencing-based multigene panel testing at our institute to investigate hereditary genetic variants for suspected hereditary breast cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 36 women who underwent multigene panel testing: 8 (22.2%) had a pathogenic variant, with or without other variants of uncertain significance (VUSs); 15 (41.7%) had VUSs only; and 13 (36.1%) had negative genetic test results. Of the eight pathogenic variants, five were <jats:italic>BRCA2<\/jats:italic> variants and one each were <jats:italic>BRCA1<\/jats:italic>, <jats:italic>MLH1,<\/jats:italic> and <jats:italic>RINT1<\/jats:italic> variants. The VUSs included <jats:italic>BRCA1<\/jats:italic> and <jats:italic>BRCA2<\/jats:italic>, as well as other breast cancer-associated genes, such as <jats:italic>ATM<\/jats:italic>, <jats:italic>CDH1<\/jats:italic>, <jats:italic>CHEK2<\/jats:italic>, and <jats:italic>PALB2<\/jats:italic>. Referring to the latest ClinVar database, one of the variants identified as a VUS at diagnosis was re-determined as likely pathogenic, and three of the variants identified as VUSs at diagnosis were re-determined as benign.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>VUSs are frequently identified during testing and it is important to monitor these individuals because VUS evaluations can change over time.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s00595-025-02994-3","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T07:20:31Z","timestamp":1737357631000},"page":"1061-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Germline variants detected by multigene panel testing in patients with suspected hereditary breast cancer"],"prefix":"10.1007","volume":"55","author":[{"given":"Yusa","family":"Togashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Nagahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Kashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chinatsu","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mako","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tsubamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Sawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Miyoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2994_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","volume":"31","author":"K Katanoda","year":"2021","unstructured":"Katanoda K, Hori M, Saito E, Shibata A, Ito Y, Minami T, et al. Updated trends in cancer in Japan: Incidence in 1985\u20132015 and mortality in 1958\u20132018-A sign of decrease in cancer incidence. J Epidemiol. 2021;31:426\u201350.","journal-title":"J Epidemiol."},{"key":"2994_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12282-023-01532-8","volume":"31","author":"Y Sagara","year":"2024","unstructured":"Sagara Y, Kumamaru H, Niikura N, Miyashita M, Konishi T, Iwamoto T, et al. 2020 Annual Report of National Clinical Database-Breast Cancer Registry: 10-year mortality of elderly breast cancer patients in Japan. Breast Cancer. 2024;31:179\u201384.","journal-title":"Breast Cancer."},{"key":"2994_CR3","doi-asserted-by":"publisher","first-page":"8297","DOI":"10.1158\/0008-5472.CAN-06-0503","volume":"66","author":"KE Malone","year":"2006","unstructured":"Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 2006;66:8297\u2013308.","journal-title":"Cancer Res."},{"key":"2994_CR4","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/npjgenmed.2015.3","volume":"1","author":"ESY Wong","year":"2016","unstructured":"Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, et al. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. NPJ Genom Med. 2016;1:15003.","journal-title":"NPJ Genom Med."},{"key":"2994_CR5","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1038\/s41467-018-06581-8","volume":"9","author":"Y Momozawa","year":"2018","unstructured":"Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, et al. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018;9:4083.","journal-title":"Nat Commun."},{"key":"2994_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s10147-017-1208-9","volume":"23","author":"H Yamauchi","year":"2018","unstructured":"Yamauchi H, Takei J. Management of hereditary breast and ovarian cancer. Int J Clin Oncol. 2018;23:45\u201351.","journal-title":"Int J Clin Oncol."},{"key":"2994_CR7","first-page":"1265","volume":"52","author":"S Ohsumi","year":"2022","unstructured":"Ohsumi S, Nakamura S, Miyata H, Watanabe C, Den H, Arai M. Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC. Jpn J Clin Oncol. 2022;52:1265\u20139.","journal-title":"Jpn J Clin Oncol."},{"key":"2994_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384:440\u201351.","journal-title":"N Engl J Med."},{"key":"2994_CR9","doi-asserted-by":"publisher","first-page":"e216744","DOI":"10.1001\/jamaoncol.2021.6744","volume":"8","author":"N Mavaddat","year":"2022","unstructured":"Mavaddat N, Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, Keeman R, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes. JAMA Oncol. 2022;8:e216744.","journal-title":"JAMA Oncol."},{"key":"2994_CR10","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1913948","volume":"384","author":"L Dorling","year":"2021","unstructured":"Dorling L, Carvalho S, Allen J, Gonz\u00e1lez-Neira A, Luccarini C, Wahlstr\u00f6m C, et al. Breast cancer risk genes - Association analysis in more than 113,000 women. N Engl J Med. 2021;384:428\u201339.","journal-title":"N Engl J Med."},{"key":"2994_CR11","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10549-023-07137-1","volume":"203","author":"L Westbrook","year":"2024","unstructured":"Westbrook L, Miltenburg D, Souter V, Maisenbacher MK, Howard KL, Sha Y, et al. Hereditary cancer testing in a diverse sample across three breast imaging centers. Breast Cancer Res Treat. 2024;203:365\u201372.","journal-title":"Breast Cancer Res Treat."},{"key":"2994_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.annonc.2022.10.004","volume":"34","author":"C Sessa","year":"2023","unstructured":"Sessa C, Balma\u00f1a J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023;34:33\u201347.","journal-title":"Ann Oncol."},{"key":"2994_CR13","first-page":"292","volume":"38","author":"P Kleiblov\u00e1","year":"2024","unstructured":"Kleiblov\u00e1 P, Novotn\u00fd J, Cibula D, Curtisov\u00e1 V, Dubov\u00e1 O, Foretov\u00e1 L, et al. The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024). Klin Onkol. 2024;38:292\u20139.","journal-title":"Klin Onkol."},{"key":"2994_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00211","volume":"2","author":"M Nagahashi","year":"2018","unstructured":"Nagahashi M, Ling Y, Hayashida T, Kitagawa Y, Futamura M, Yoshida K, et al. Actionable gene alterations in an Asian population with triple-negative breast cancer. JCO Precis Oncol. 2018;2:1.","journal-title":"JCO Precis Oncol."},{"key":"2994_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/cas.13837","volume":"110","author":"M Nagahashi","year":"2019","unstructured":"Nagahashi M, Shimada Y, Ichikawa H, Kameyama H, Takabe K, Okuda S, et al. Next generation sequencing-based gene panel tests for the management of solid tumors. Cancer Sci. 2019;110:6\u201315.","journal-title":"Cancer Sci."},{"key":"2994_CR16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3892\/ol.2022.13238","volume":"23","author":"V Ozmen","year":"2022","unstructured":"Ozmen V, Caglayan AO, Yararbas K, Ordu C, Aktepe F, Ozmen T, et al. Importance of multigene panel test in patients with consanguineous marriage and family history of breast cancer. Oncol Lett. 2022;23:118.","journal-title":"Oncol Lett."},{"key":"2994_CR17","doi-asserted-by":"publisher","first-page":"e2232787","DOI":"10.1001\/jamanetworkopen.2022.32787","volume":"5","author":"PW Whitworth","year":"2022","unstructured":"Whitworth PW, Beitsch PD, Patel R, Rosen B, Compagnoni G, Baron PL, et al. Clinical utility of universal germline genetic testing for patients with breast cancer. JAMA Netw Open. 2022;5:e2232787.","journal-title":"JAMA Netw Open."},{"key":"2994_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12282-022-01342-4","volume":"29","author":"S Hayashi","year":"2022","unstructured":"Hayashi S, Kubo M, Kaneshiro K, Kai M, Yamada M, Morisaki T, et al. Genetic medicine is accelerating in Japan. Breast Cancer. 2022;29:659\u201365.","journal-title":"Breast Cancer."},{"key":"2994_CR19","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.21873\/anticanres.15907","volume":"42","author":"S Hayashi","year":"2022","unstructured":"Hayashi S, Kubo M, Matsuzaki S, Kai M, Morisaki T, Yamada M, et al. Significance of the multi-gene panel myRisk in Japan. Anticancer Res. 2022;42:4097\u2013102.","journal-title":"Anticancer Res."},{"key":"2994_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/jog.16026","author":"M Nakahara","year":"2024","unstructured":"Nakahara M, Ushiama M, Tanabe N, Gotoh M, Sakamoto H, Yoshida T, et al. Multi-gene panel analysis in BRCA1\/2-negative patients suspected of hereditary breast and ovarian cancer syndrome: Real-world data from a single institution. J Obstet Gynaecol Res. 2024. https:\/\/doi.org\/10.1111\/jog.16026.","journal-title":"J Obstet Gynaecol Res."},{"key":"2994_CR21","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/tbj.13971","volume":"26","author":"S Reid","year":"2020","unstructured":"Reid S, Pal T. Update on multi-gene panel testing and communication of genetic test results. Breast J. 2020;26:1513\u20139.","journal-title":"Breast J."},{"key":"2994_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1136\/jmg-2023-109488","volume":"61","author":"N Walsh","year":"2024","unstructured":"Walsh N, Cooper A, Dockery A, O\u2019Byrne JJ. Variant reclassification and clinical implications. J Med Genet. 2024;61:207\u201311.","journal-title":"J Med Genet."},{"key":"2994_CR23","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1053\/j.gastro.2015.05.006","volume":"149","author":"MB Yurgelun","year":"2015","unstructured":"Yurgelun MB, Allen B, Kaldate RR, Bowles KR, Judkins T, Kaushik P, et al. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology. 2015;149:604\u201313.","journal-title":"Gastroenterology."},{"key":"2994_CR24","doi-asserted-by":"publisher","first-page":"e0213746","DOI":"10.1371\/journal.pone.0213746","volume":"14","author":"SGW Ow","year":"2019","unstructured":"Ow SGW, Ong PY. Lee SC Discoveries beyond BRCA1\/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world. PLoS One. 2019;14:e0213746.","journal-title":"PLoS One."},{"key":"2994_CR25","doi-asserted-by":"publisher","first-page":"1271710","DOI":"10.3389\/fgene.2023.1271710","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu Y, Zheng J, Xu Y, Lv J, Wu Z, Feng K, et al. Multigene testing panels reveal pathogenic variants in sporadic breast cancer patients in northern China. Front Genet. 2023;14:1271710.","journal-title":"Front Genet."},{"key":"2994_CR26","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1038\/s41598-022-07383-1","volume":"12","author":"RSC Guindalini","year":"2022","unstructured":"Guindalini RSC, Viana DV, Kitajima J, Rocha VM, L\u00f3pez RVM, Zheng Y, et al. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022;12:4190.","journal-title":"Sci Rep."},{"key":"2994_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/gim.2017.207","volume":"20","author":"S Macklin","year":"2018","unstructured":"Macklin S, Durand N, Atwal P. Hines S Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. Genet Med. 2018;20:346\u201350.","journal-title":"Genet Med."},{"key":"2994_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/humu.22956","volume":"37","author":"S Moghadasi","year":"2016","unstructured":"Moghadasi S, Eccles DM, Devilee P, Vreeswijk MP. van Asperen CJ Classification and Clinical Management of Variants of Uncertain Significance in High Penetrance Cancer Predisposition Genes. Hum Mutat. 2016;37:331\u20136.","journal-title":"Hum Mutat."},{"key":"2994_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10549-016-3944-3","volume":"159","author":"N Li","year":"2016","unstructured":"Li N, Thompson ER, Rowley SM, McInerny S, Devereux L, Goode D, et al. Reevaluation of RINT1 as a breast cancer predisposition gene. Breast Cancer Res Treat. 2016;159:385\u201392.","journal-title":"Breast Cancer Res Treat."},{"key":"2994_CR30","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ajhg.2019.05.011","volume":"105","author":"MA Cousin","year":"2019","unstructured":"Cousin MA, Conboy E, Wang JS, Lenz D, Schwab TL, Williams M, et al. RINT1 Bi-allelic Variations Cause Infantile-Onset Recurrent Acute Liver Failure and Skeletal Abnormalities. Am J Hum Genet. 2019;105:108\u201321.","journal-title":"Am J Hum Genet."},{"key":"2994_CR31","doi-asserted-by":"publisher","first-page":"e162836","DOI":"10.1172\/JCI162836","volume":"133","author":"N Launay","year":"2023","unstructured":"Launay N, Ruiz M, Planas-Serra L, Verdura E, Rodr\u00edguez-Palmero A, Schl\u00fcter A, et al. RINT1 deficiency disrupts lipid metabolism and underlies a complex hereditary spastic paraplegia. J Clin Invest. 2023;133:e162836.","journal-title":"J Clin Invest."}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-02994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-025-02994-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-02994-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:26:53Z","timestamp":1757129213000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-025-02994-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1007\/s00595-025-02994-3","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"type":"print","value":"0941-1291"},{"type":"electronic","value":"1436-2813"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"4 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M Nagahashi received honoraria from Chugai, AstraZeneca, Eli Lilly, Pfizer, Novartis, Taiho, Daiichi Sankyo, Esai, Kyowa-Kirin, MSD,\u00a0and Denka. Y Miyoshi received research funding and honoraria from Esai, Chugai, AstraZeneca, Eli Lilly, Pfizer, MSD, Kyowa-Kirin, Daiichi-Sankyo, and Taiho.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}